If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Researchers at the University of Michigan found that 80 percent of participants with suspected dementia had not been told they had the disease or showed early signs.

About 40% of dementia cases could be prevented or delayed by healthy lifestyle choices and preventive medicine. Here's a tool to gauge your brain care and track your progress.

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

Intra-Cellular’s promising clinical-stage pipeline includes treatments for a wide range of neurological indications.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in a adults with Parkinson’s disease whose ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.